Allena Pharmaceuticals (Allena Pharmaceuticals) FCF Margin % : 0.00% (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Allena Pharmaceuticals's Free Cash Flow for the three months ended in Jun. 2022 was $-4.56 Mil. Allena Pharmaceuticals's Revenue for the three months ended in Jun. 2022 was $0.00 Mil. Therefore, Allena Pharmaceuticals's FCF Margin % for the quarter that ended in Jun. 2022 was 0.00%.

As of today, Allena Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Allena Pharmaceuticals's FCF Margin % or its related term are showing as below:

ALNAQ's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.24
* Ranked among companies with meaningful FCF Margin % only.

Allena Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Allena Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals FCF Margin % Chart

Allena Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

FCF Margin %

Get a 7-Day Free Trial

Allena Pharmaceuticals Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Allena Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Allena Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allena Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's FCF Margin % falls into.

Allena Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Allena Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-46.345	/	0
	=	%

Allena Pharmaceuticals's FCF Margin for the quarter that ended in Jun. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	-4.557	/	0
	=	%

Allena Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Newton Executive Park, Suite 202, Newton, MA, USA, 02462

Website

https://www.allenapharma.com

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Executives

Louis Md Brenner	officer: See Remarks	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick	director	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz	officer: Chief Financial Officer	4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan	officer: Chief Financial Officer	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p.	10 percent owner	C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp	10 percent owner	11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper	director, 10 percent owner	550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper	director, 10 percent owner	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin	director, officer: Chief Executive Officer	C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139